INTERSECT ENT: Changing the treatment paradigm for patients with chronic sinus disease

Headquartered in Menlo Park, California, Intersect ENT Inc., is a growth-stage drug-device company focused on advancing clinically proven therapy solutions that improve quality of life for patients with ear, nose and throat conditions.
www.intersectent.com

XENT Stock Activity
Intersect Infographic

PROPEL

The company’s initial products, the PROPEL and PROPEL mini dissolvable steroid-releasing implants, are the only products backed by Level 1-A clinical evidence to improve sinus surgery outcomes for patients suffering from chronic sinusitis.